Sage Therapeutics, Inc. (NASDAQ:SAGE) Given New $120.00 Price Target at Royal Bank Of Canada

Sage Therapeutics, Inc. (NASDAQ:SAGE) had its price target upped by Royal Bank Of Canada from $117.00 to $120.00 in a research note published on Thursday, November 2nd.

Other equities research analysts also recently issued research reports about the company. Canaccord Genuity dropped their target price on Sage Therapeutics from $110.00 to $81.00 and set a buy rating for the company in a research report on Tuesday, September 12th. Stifel Nicolaus assumed coverage on Sage Therapeutics in a research report on Wednesday, August 9th. They set a buy rating and a $104.00 target price for the company. Cowen and Company reiterated a buy rating and issued a $100.00 price objective on shares of Sage Therapeutics in a report on Friday, August 4th. Needham & Company LLC set a $95.00 price objective on Sage Therapeutics and gave the company a buy rating in a report on Friday, August 4th. Finally, BidaskClub downgraded Sage Therapeutics from a strong-buy rating to a buy rating in a report on Monday, July 31st. Three investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of Buy and an average target price of $102.29.

Sage Therapeutics (NASDAQ:SAGE) traded down $6.40 during trading on Thursday, reaching $88.25. The company’s stock had a trading volume of 1,901,500 shares, compared to its average volume of 532,001. Sage Therapeutics has a one year low of $44.55 and a one year high of $99.80.

Sage Therapeutics (NASDAQ:SAGE) last released its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.97) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.98) by $0.01. Sage Therapeutics’s quarterly revenue was up .0% compared to the same quarter last year. sell-side analysts expect that Sage Therapeutics will post -7.36 EPS for the current year.

WARNING: This report was originally posted by BBNS and is the sole property of of BBNS. If you are accessing this report on another site, it was illegally copied and reposted in violation of US and international trademark and copyright law. The correct version of this report can be viewed at https://baseballnewssource.com/markets/sage-therapeutics-inc-sage-pt-raised-to-120-00/1752489.html.

Several hedge funds have recently bought and sold shares of the company. BlackRock Inc. boosted its position in shares of Sage Therapeutics by 5.9% during the second quarter. BlackRock Inc. now owns 3,031,548 shares of the biopharmaceutical company’s stock worth $241,431,000 after buying an additional 168,424 shares during the period. Vanguard Group Inc. boosted its position in shares of Sage Therapeutics by 2.2% during the second quarter. Vanguard Group Inc. now owns 2,749,954 shares of the biopharmaceutical company’s stock worth $219,006,000 after buying an additional 58,679 shares during the period. Bank of New York Mellon Corp boosted its position in shares of Sage Therapeutics by 36.5% during the third quarter. Bank of New York Mellon Corp now owns 2,710,027 shares of the biopharmaceutical company’s stock worth $168,834,000 after buying an additional 724,494 shares during the period. State Street Corp boosted its position in shares of Sage Therapeutics by 7.7% during the second quarter. State Street Corp now owns 1,212,384 shares of the biopharmaceutical company’s stock worth $96,558,000 after buying an additional 87,097 shares during the period. Finally, Oak Ridge Investments LLC boosted its position in shares of Sage Therapeutics by 0.9% during the third quarter. Oak Ridge Investments LLC now owns 736,709 shares of the biopharmaceutical company’s stock worth $45,897,000 after buying an additional 6,835 shares during the period.

About Sage Therapeutics

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Analyst Recommendations for Sage Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
MLB Commissioner: New Rule for Pace-of-Play in 2018
MLB Commissioner: New Rule for Pace-of-Play in 2018
Alex Cobb Could Be Good Fit for Cubs
Alex Cobb Could Be Good Fit for Cubs
Joey Votto Is One of Baseball’s Best Hitters
Joey Votto Is One of Baseball’s Best Hitters
Hunter Pence May Become Part-Time Player
Hunter Pence May Become Part-Time Player
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts


Leave a Reply

 
© 2006-2017 BBNS.